Bristol-Meyers Squibb and Sanofi Plavix Patent Upheld
Posted by T. Williams on 09/04/07
Industry: Pharmaceutical
Defendant: Apotex, Inc.
Plaintiff: Bristol-Meyers Squibb, Co. and Sanofi –Aventies SA
Jurisdiction: U.S. District Court, Southern District of New York
Result: Judgment
Source: Wall Street Journal, “Plavix Ruling Gives Bristol, Sanofi Options,” June 20, 2007.
Industry: Pharmaceutical
Defendant: Apotex, Inc.
Plaintiff: Bristol-Meyers Squibb, Co. and Sanofi –Aventies SA
Jurisdiction: U.S. District Court, Southern District of New York
Result: Judgment
Source: Wall Street Journal, “Plavix Ruling Gives Bristol, Sanofi Options,” June 20, 2007.
Apotex, Inc. of Canada can no longer pursue its current plan to bring a generic version of Plavix into the U.S. market, now that the District Court Judge in the Southern District of New York upheld the patent held by Bristol-Meyers Squibb. Plavix brought $5.8M in sales in 2006, and is believed that sales would have been even greater had the generic version of Apotex not been introduced.
Unless Apotex appeals, the ruling allows exclusivity with Plavix until the patent expires in 2011.
